Ensayos clínicos

Inclusion Criteria:

• From Lung Archive - IBB # 442-99
  • Cancer cases, n=100 (adeno 50, squamous 40, other 10)
  • Disease controls (benign lung nodules), n=50
• From Prospective Case Cohort
  • Cancer cases, n=150 (distribution roughly same as for archival cases)
• From Parallel Control Study, n=2000 - IRB #15-006191
  • Controls matched on age, sex, and smoking history will be selected from this larger parallel study (at least 300 independent controls for each case group).
• For exploratory Disease Control group (Aim 4), 4 ml (minimum of 2 ml) plasma will be requested for each of following tumor subsets:
  • Lymphoma, n=20 (any stage or site, at least 10 non-Hodgkins)
    • Obtained from Dr. Thomas Witzig’s Lymphoma SPORE registry (IRB # 118-01)
  • Thyroid, n=20 (any stage, at least half non-papillary)
    • Obtained prospectively from Oncology calendars
  • Breast, n=20 (stage (half I-II, half III-IV), ER status (half positive, half negative)
    • Obtained from Dr. Fergus Couch and Janet Olson’s Breast Cancer Registry (IRB # 1815-04)
  • Prostate, n=20 (half Gleason’s 6 or less, half Gleason’s 7 or higher)
    • Obtained from Dr. Matthew Gettman’s Prostate protocol (IRB # 15-009309)
  • Gynecologic, n=20 (Ovarian, n=10 (any stage or type); Uterine, n=10 (any stage or type))
    • Ovarian obtained from Dr. Kimberly Kalli’s Ovarian Cancer registry (IRB#08-005749)
    • Uterine obtained from Dr. Sean Dowdy’s Endometrial cancer bank (IRB # 2405-04)
  • Kidney, n=20 (any stage or type)
    • Obtained from Dr. R. Houston Thompson’s (IRB # 14-03)
  • Esophagus, n=20 (any stage, type (10 adeno, 10 squamous cell))
    • Obtained from Dr. Navtej Buttar’s Esophageal Biospecimen Registry (IRB #495-01)
  • Stomach, n=20 (any stage or type)
    • Obtained from Dr. Lisa Boardman’s GI Tumor Registry (IRB # 622-00)
  • Liver, n=20 (any stage)
    • Obtained from Dr. Lewis Roberts’ Liver Registry (RB # 707-03)
  • Pancreas, n=20 (any stage)
    • Obtained from Dr. David Ahlquist’s Compartmentalization study (IRB # 15-001127)
  • Colorectum, n=20 (stage (half I-II, half III-IV)
    • Obtained from Dr. Lisa Boardman’s GI Tumor Registry (IRB # 622-00) or Dr. David Ahlquist’s Compartmentalization study (IRB # 15-001127)

Exclusion Criteria:

• Known primary cancer outside of the lungs within the last 5 years (not including basal cell or squamous cell skin cancers) (primary aim only)
• Current target pathology is a recurrence
• Prior or active chemotherapy or radiation for the primary lung cancer (primary aim only)
• Patient has had a transplant
• Inability to give informed consent (prospective groups only)